Efficacy of a novel artificial liver versatile plasma purification system in patients with acute-on-chronic liver failure

Figure 1 Flow diagram. A: Flow chart; B: Schematic of versatile plasma purification system (VPPS) treatment; C: VPPS treatment was performed by combining a blood separation system and hemodialysis unit. VPPS: Versatile plasma purification system.

Figure 2 Changes in laboratory results between versatile plasma purification system and non-versatile plasma purification system groups. The laboratory results were evaluated at six distinct time points: T1: Upon admission; T2-T5: Prior to and following artificial liver support treatment; T6: Immediately before discharge. ^aP < 0.05; ^bP < 0.01; and ^cP < 0.001 compared with the control group; ALS: Artificial liver support; VPPS: Versatile plasma purification system; ALT: Glutamic-pyruvic transaminase; AST: Glutamic oxaloacetic transaminase; TBIL: Total bilirubin; TBA: Total bile acid; AFP: Alpha-fetoprotein; ALB: Albumin; GLO: Globulin; CRE: Creatinine; PTA: Prothrombin activity; HB: Hemoglobin; PLT: Platelet; BUN: Blood urea nitrogen; INR: International normalized ratio; WBC: White blood cell; PCT: Procalcitonin.

Figure 3 Kaplan-Meier curves for time to rehospitalization, and all-cause mortality in patients with versatile plasma purification system and non-versatile plasma purification system groups during the years of follow-up. A: Kaplan-Meier curves for time to rehospitalization; B: All-cause mortality. VPPS: Versatile plasma purification system.